COPD
Non-invasive ventilation touted for COPD treatment at respiratory meeting
September 6, 2016Manufacturing and Production, Research and Development COPD, resmed
ResMed has presented results at the European Respiratory Society international congress, touting home non-invasive ventilation (NIV) as part of a …
GSK triple combo COPD therapy shows superiority in Phase III trials
June 20, 2016Research and Development, Sales and Marketing COPD, GSK, phase III
GlaxoSmithKline (LSE: GSK), along with Innoviva (NASDAQ: INVA), have presented positive top-line results from a pivotal Phase III trial for …
GSK says asthma drug Breo shows superior results over standard care in major study
May 24, 2016Research and Development, Sales and Marketing COPD, GSK, asthma, breo, drug trial
UK drugmaker GlaxoSmithKline (LSE: GSK) on Tuesday said inhaled medicine Breo proved significantly better than standard care in a major …
AstraZeneca’s COPD therapy gets US FDA approval
April 26, 2016Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval
UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …
AstraZeneca buys rights to Orexo respiratory programme
March 21, 2016Sales and Marketing AstraZeneca, COPD, asthma, orexo
AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million. The deal centres on the …
Novartis and Qualcomm to develop smart inhaler technology for COPD
January 8, 2016Manufacturing and Production, Medical Communications COPD, Novartis, Qualcomm Life, breezhaler, digital inhaler, qualcomm
Novartis has enlisted Qualcomm life to help the pharma giant develop the ‘next generation’ of its Breezhaler device for patients …
GSK collaborates on ‘smart inhaler’ technology for respiratory trials
December 3, 2015Research and Development COPD, GSK, Propeller, Propeller Health, asthma, clinical trials, ellipta, inhalers, smart drugs, smart inhalers
GSK has entered the ‘smart drug’ industry by partnering with a health technology company to develop a sensor for use …
Raising Awareness: World COPD Day
November 18, 2015Medical Communications COPD, COPD disease, COPD exacerbation, Synergy Vision, disease awareness, medical communications
World COPD Day 18th November 2015
Verona Pharma’s respiratory drug proves positive in study
October 1, 2015Research and Development COPD, verona pharma
Verona Pharma has announced encouraging positive headline data of the third and final part of a randomised, clinical study in …
Genetic study reveals new associations with lung disease and smoking behaviour
September 25, 2015Medical Communications, Research and Development COPD, lung cancer, smkoing
New research published in The Lancet Respiratory Medicine and presented at this year’s European Respiratory Society (ERS) Congress in Amsterdam …
Boehringer and BioMed X crowdsource top scientists to fight COPD
September 23, 2015Research and Development Boehringer Ingelheim, COPD
Boehringer Ingelheim and BioMed X have used a crowdsourcing strategy to establish a global research team to collaborate on the …
GSK suffers Breo late-stage trial blow
September 9, 2015Research and Development COPD, GSK, Revlar, asthma, breo, clinical trial, phase III
GSK has hit a setback in its plans to expand sales of its blockbuster asthma treatment Breo, after a major …
MRC, GSK and universities team up on inflammatory diseases
July 15, 2015Research and Development COPD, GSK, MRC, Medical Research Council, fibrosis, inflammatory diseases
UK pharma giant GSK is partnering with the Medical Research Council, to study the biological mechanisms behind common inflammatory diseases. …
Boehringer Ingelheim launches Spiolto for COPD
July 2, 2015Sales and Marketing Boehringer Ingelheim, COPD, Europe, Spiolto, Spiriva, Striverdi
Boehringer Ingelheim is beginning a new push in lung disease across Europe after being approved by regulators in nine countries …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
Latest content
Five Facts about cardiovascular disease
